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Objective: The study was designed to investigate the effectiveness of orally administered misoprostol versus intravenous 
ergometrine (stored at tropical temperatures) in the prevention of primary postpartum hemorrhage (PPH) among parturients 
undergoing vaginal delivery in a teaching hospital.
Study Design: A double‑blind randomized controlled clinical trial was conducted at the University of Benin Teaching Hospital. 
One hundred and fifty parturients were offered 400 ug misoprostol and an intravenous placebo for the management of the 
third stage of labor while another 150 parturients received oral placebo and 0.5 mg intravenous ergometrine.
Results: There was no significant difference in the incidence of PPH (blood loss > 500 ml) between the two groups: 8 (5.3%) 
for the misoprostol group compared with 7 (4.7%) for the ergometrine group (P = 0.79, relative risk (RR) = 1.07, confidence 
interval (CI): 0.66–1.74). The incidence of severe PPH (blood loss > 1000 ml) was similar between the two groups: 2 (1.3%) 
in the misoprostol group compared with 1 (0.7%) in the ergometrine group. Similarly, the indices of postpartum blood 
loss (hematocrit change, need for blood transfusion, and surgical intervention) were comparable between the two groups. 
A subgroup analysis of high‑risk parturients revealed comparable indices. The misoprostol group, however, had a significantly 
higher risk of shivering in the early postpartum period (P = 0.00, RR = 2.01, CI: 1.69–2.38).
Conclusions: The results suggest that oral misoprostol has comparable efficacy to intravenous ergometrine at tropical 
conditions in the prevention of PPH. However, in view of its easier mode of administration, oral misoprostol may be preferable 
in rural situations in Africa.
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Introduction
Postpartum hemorrhage (PPH) is a major cause of maternal 
mortality and morbidity in developing countries, accounting 
for between 10 and 50 percent of maternal deaths.[1-3] 
Primary PPH is estimated to account for approximately 28% of 
pregnancy-related deaths on a worldwide basis[1] and hence 
projected to account for over 125,000 deaths annually in 
developing countries.[2] In over 50% of cases, this is often 
due to uterine atony.[4,5]
A hospital-based study in Nigeria reported PPH as the single 
most important cause of maternal mortality.[6] Similarly, 
a study in the Gambia showed that PPH accounted for 
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33% of maternal deaths and was the leading cause of 
death.[7] Although there is good evidence that prophylaxis 
with oxytocic drugs in the third stage of labor is effective 
in preventing PPH resulting from uterine atony, its use in 
developing countries, especially in tropical environments, 
poses certain peculiar challenges.[8]
The most daunting of this may perhaps be the finding that 
routinely administered uterotonics lose  as much as a third 
of its potency when stored in a tropical environment for only 
one month.[9] Arguably, this may be a contributing factor 
in maternal mortality resulting from PPH in many tropical 
countries. This has informed the need for the development 
of more stable uterotonics with a longer shelf life in tropical 
climatic conditions.[10]
While the need for the development of a more stable 
uterotonic remains a priority at all levels of care in the 
tropics, the need for an orally active uterotonic is particularly 
important in peripheral units of care.[8] These facilities 
are least served by blood banking facilities, personnel, 
manpower, and the most basic of facilities including syringes 
and needles. Thus, for the effective prevention of PPH, the 
use of an orally active uterotonic administered with the 
minimal requirement will undoubtedly prove indispensable.
One drug that has been shown to have the above properties is 
misoprostol,[8,11,12] an orally active, inexpensive prostaglandin 
analog. Earlier observational studies have shown a reduction 
in the incidence of PPH following its use, or when compared 
with a placebo.[11,12] These studies have been carried out 
predominantly in developed countries, where the risk and 
significance of postpartum blood loss may not be similar to 
that of developing countries. In any case, there is a need 
for further studies the principle of which is to determine 
the relative efficacy of orally administered misoprostol and 
currently administered uterotonic agents stored in tropical 
conditions. The findings from such a study will inform the use 
or non-use of oral misoprostol in the prevention of primary 
PPH especially in tropical conditions.
Objectives
1. To investigate the efficacy of orally administered 
misoprostol versus parenteral ergometrine in the 
prevention of primary PPH
2. To investigate the need for additional oxytocic treatment 
or blood transfusion in both treatment arms
3. To determine whether any particular subgroup of 
parturient at risk of PPH (using previously identified risk 
criteria for PPH) would benefit more or less than others 
in the respective treatment groups
4. To make recommendations on effective methods for 
preventing PPH in the tropics.
Materials and Methods
Sample size
The primary null hypothesis is that there is no difference 
between the use of ergometrine and misoprostol in the 
prevention of primary PPH. The sample size of 286 in both 
treatment arms was calculated to give an 80% chance of 
detecting a reduction in blood loss >500 ml of 15% to 4.5%. 
These ranges of values were determined from previous 
studies on actively managed labor reporting an incidence 
in the range of 2.5% to 14.8%.[13-17] Ethical Approval was 
obtained from the University of Benin Teaching Hospital 
Ethics Committee dated 4th January 1999.
Recruitment of cases
The study was a hospital-based double-blind randomized 
controlled clinical trial, at the University of Benin Teaching 
Hospital, Benin City, Nigeria. All women undergoing vaginal 
delivery beyond 28 weeks of pregnancy were enrolled in the 
study. Women were not eligible for enrollment if they had 
significantly elevated blood pressure at the antenatal clinic or 
in the course of labor (diastolic blood pressure >100 mmHg) 
or if cesarean section was already planned, or if they were 
not willing or able to give informed consent.
Women were approached on admission to the labor 
ward for consent and to determine if they were eligible 
for participation in the trial. The women in labor were 
randomized into two groups using computer-generated 
random numbers. Eligible women were requested to 
randomly select from a pool of random numbers. Each 
number was matched with similarly numbered sealed 
treatment packs containing prepackaged mixtures. Each 
treatment pack contained four powdered tablets and a 
syringe and needle containing 2 ml of sterile solution. The 
packs were identical in shape, color, and weight. Each woman 
was administered the intravenous injection at the delivery of 
the anterior shoulder (or after delivery if breech and multiple 
pregnancies) and four powdered tablets orally with 50 ml 
of water after delivery. Thus, the trial was double-blinded 
using double placebos. The content of each syringe was to 
be discarded and reconstituted if it was not used within 48 
hours, to maintain sterility of the parenteral injections. No 
pack lasted beyond this time frame.
Management of labor
During the second stage of labor, when there was reasonable 
certainty that vaginal delivery would occur, the packs 
were opened at the patient’s bedside and all preparations 
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completed to administer the oral tablets and parenteral 
injection. If for any reason the contents of the pack were 
returned, the content was to be discarded and the oral 
drugs re-circulated in the pool. This task was assigned to a 
different individual from the principal investigator. No pack 
was however returned during the study period. The identity 
of the packs was revealed only on completion of the project.
Each woman enrolled in the study, received misoprostol 
400 ug or ergometrine 0.5 mg. The misoprostol group 
received four powdered tablets each of 100 ug misoprostol 
and a placebo injection while the ergometrine group received 
2 ml of 0.5 mg ergometrine intravenously and oral placebo. 
The third stage of labor was managed actively as currently 
practiced in the department. The active management consists 
of the use of a uterotonic agent, clamping, and cutting of 
the umbilical cord immediately after delivery of the infant 
and suprapubic pressure with controlled cord traction on 
palpation of uterine contraction without awaiting signs of 
placenta separation.
The attending midwife estimated blood loss. Blood was 
collected in a bedpan at delivery and continued for at 
least 2 hours after delivery in the labor ward. This was 
the minimum time a patient is observed in the labor ward 
after delivery before transfer to the ward if there are no 
complications. The estimated blood loss was the sum of the 
measured blood loss and visual estimation of the soaked 
pads and beddings. Perineal trauma (episiotomy, first or 
second-degree tear) was sutured promptly if present. The 
women were carefully observed for features of excessive 
blood loss, if signs were present, an active intervention was 
commenced with intravenous ergometrine 0.5 mg and if 
bleeding persisted 20IU oxytocin infused in 500 ml of 0.9% 
saline infusion. Further therapeutic measures were taken 
as deemed appropriate. A detailed recording of all events 
especially in the third stage of labor as well as possible 
adverse effects were also done. The attending physician 
completed the data sheets.
Data analysis
The completed data sheets were collected by the principal 
investigator but only collated and analyzed at the completion 
of the study. Though provision for an interim analysis was 
made in the design of the project, this was not required. All 
data were entered into a database (Epi-Info 6: Centre for 
Disease Control and Prevention, Atlanta) before breaking 
the randomization code for analysis. The results are 
reported on an intention to treat basis. Comparisons were 
by the Chi-square test or Fisher’s exact test with calculated 
relative risk (RR) and 95% confidence intervals (CIs) for 
non-continuous variables and by the Mann–Whitney test for 
continuous variables.
The Ethical Research Committee of the University of Benin 
Teaching Hospital, Benin City, Nigeria approved the study.
Results
The trial involved 300 women: 150 received 400 mg of 
misoprostol orally and a parenteral placebo while the other 
150 received parenteral ergometrine 0.5 mg and oral placebo. 
Table 1 shows the baseline characteristics and obstetrics 
history of parturients included in the trial. Both groups were 
comparable at entry into the trial. Table 2 provides data on 
intrapartum and immediate postpartum clinical sequelae in 
both trial groups. The two groups were comparable based on 
type of labor, duration of labor, intrapartum use of oxytocin, 
type of delivery, and genital injuries.
Table 1: Baseline Characteristics
Misoprostol (n=150) Ergometrine (n=150) P
Age 30.1 (5.1) 30.0 (4.8) 0.84
Height (cm) 163.4 (7.2) 164.4 (7.2) 0.29
Weight (kg) 70.8 (11.9) 71.9 (11.9) 0.42
BMI 26.4 (4.1) 26.7 (4.0) 0.52
SBP (mmHg) 126.2 (12.5) 123.7 (14.1) 0.10
DBP (mmHg) 78.1 (8.9) 77.7 (8.8) 0.69
Gestational age 38.7 (1.9) 37.6 (6.0) 0.24
Nullipara 42 (28.0) 41 (27.3) 0.90
Para 1‑3 84 (56.0) 90 (60) 0.48
Para ≥4 24 (16.0) 19 (12.7) 0.41
Hematocrit 32.8 (3.3) 32.8 (3.3) 0.95 
BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure







Spontaneous 97 (64.7) 104 (69.3) 0.39 
Augmented 26 (17.3) 26 (17.3) 1.00 
Induced 27 (18.0) 20 (13.3) 0.26
Duration of first stage (min) 357.0 (270.3) 305.0 (237.9) 0.07
Mean dose of oxytocin (miu) 10.4 (19.0) 6.4 (13.4) 0.21
Duration of oxytocin use (min) 125.1 (224.9) 84.4 (169.1) 0.25
Duration of second stage (min) 10.1 (15.7) 12.5 (24.8) 0.50
Type of delivery
SVD 145 (96.7) 139 (92.7) 0.12
Ass Breech 2 (1.3) 6 (4.0) 0.14
Ventouse 1 (0.7) 4 (2.7) 0.18
Forceps 2 (1.3) 1 (0.7) 0.56
Birth weight 3.1 (0.3) 3.0 (0.3) 0.38
Episiotomy 61 (40.7) 52 (34.6) 0.28
Perineal tear 27 (18.0) 37 (24.6) 0.16
Cervical tear 3 (2.0) 2 (1.3) 0.65
SVD: Spontaneous vaginal delivery
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Table 3 describes the effect of the trial treatments on 
the third stage of labor. The incidence of PPH (blood 
loss >500 ml) was 8 (5.3%) in the misoprostol arm 
compared with 7 (4.7%) in the ergometrine treatment 
arm. This difference was not statistically significant 
(P = 0.79, RR = 1.07, CI: 0.66–1.74). The incidence of 
severe PPH (blood loss >1000 ml) was 2 (1.3%) in the 
misoprostol group and 1 (0.7%) in the ergometrine group. 
Similarly, the proportions of women requiring manual 
removal of the placenta or an additional uterotonic agent 
were similar in both groups. The table also provides a 
subgroup analysis of women with one or more identified 
risk factors for PPH based on previous studies. At-risk 
women based on these criteria included primiparity, 
grand multiparity, uterine fibroid, multiple pregnancies, 
induction/oxytocin use in labor and women with a history 
of previous PPH. In this subgroup analysis, the incidence 
of PPH (blood loss >500 ml) was 3.3% in the misoprostol 
group and 2.7% in the ergometrine group. The difference 
was not statistically significant. There was no case of 
severe PPH (blood loss >1000 ml) and the need for 
ergometrine or further oxytocin was comparable in the 
two groups.
Table 4 shows the changes in hematocrit levels between 
postpartum (2 days after delivery) and prepartum values. 
A subgroup analysis of high-risk women is also presented. 
A drop in hematocrit of more than 0.10 was 1.4% in the 
misoprostol group and 0.7% in the ergometrine group. 
Though there appeared to be a trend towards lower 
hematocrit levels in the misoprostol group the difference 
was not statistically significant.
Postpartum side effects experienced by the two groups are 
presented in Table 5. The side effects were those reported 
by parturient before discharge or on clinical observation. 
Women in the misoprostol group reported a significantly 
higher incidence of shivering. In general, a comparatively 
lower incidence of postpartum complications was reported 
in the ergometrine group.
Discussion
The results of this study suggest that oral misoprostol is of 
similar efficacy in minimizing blood loss in women in the third 
stage of labor as compared with parenteral ergometrine. The 
findings of this study are comparable with reported studies 
of misoprostol and standard uterotonic agents in third stage 
management.[18-20]
To complement the clinical observation of PPH, which is often 
underestimated, change in hematocrit was used to evaluate 
the two groups. A change in laboratory criteria as hematocrit 
or hemoglobin concentration is a more objective, and the 
American College of Obstetricians and Gynecologists suggest 
that the definition of PPH may be based on the change in 
laboratory findings in the postpartum period.[21] Using this 
outcome measure, however, both treatment modalities were 
again of similar efficacy.
A major finding from this study was the observation that 
parturients at high risk for PPH did not suffer higher 
adverse morbidity following the use of oral misoprostol 
and parenteral ergometrine. The incidences of PPH and 
hematocrit change were similar between the two groups 
Table 3: Third Stage and Its Management
Misoprostol (n=150) Ergometrine (n=150) RR (95% CI) P
Manual placenta removal 6 (4.0) 4 (2.7) 1.21 (0.72:2.03) 0.52
Duration of third stage (mins) 3.9 (10.3) 4.4 (12.4) ‑ 0.13
Blood loss >500 mls 8 (5.3) 7 (4.7) 1.07 (0.66:1.74) 0.79
Blood loss >1000 mls 2 (1.3) 1 (0.7) 1.34 (0.60:3.00) 0.56
Blood transfusion ‑ ‑ ‑ ‑
Ergometrine for PPH 26 (17.3) 21 (14.0) 1.13 (0.85:1.50) 0.43
Oxytocin for PPH 32 (21.3) 24 (16.0) 1.18 (0.91:1.53) 0.24
ERPC for products 5 (3.3) 4 (2.7) 1.11 (0.61:2.02) 0.74
Abdominal surgical intervention ‑ ‑ ‑ ‑
High risk group n=83 n=74 RR (95%CI) P
Manual placenta removal 4 (4.8) 2 (2.7) 1.27 (0.71:2.29) 0.49
Duration of third stage (mins) 2.5 (2.4) 3.0 (1.9) ‑ 0.14
Blood loss >500 mls 5 (6.0) 4 (5.4) 1.11 (0.61:2.02) 0.74
Blood loss >1000 mls ‑ ‑ ‑ ‑
Ergometrine for PPH 16 (19.3) 13 (17.6) 1.12 (0.79:1.58) 0.56
Oxytocin for PPH 21 (25.3) 20 (27.0) 1.03 (0.74:1.42) 0.87
ERPC for products ‑ ‑ ‑ ‑
ERPC: Evacuation of Retained Products of Conception; PPH: Postpartum hemorrhage
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and appeared comparable to the general population on an 
overview. Previous studies comparing oral misoprostol and 
standard treatment modalities have often excluded this 
group of parturients from randomization. The populations 
studied were often those perceived to be at low risk. Thus, 
a comparable outcome in this subgroup is an important 
evidence for the efficacy and use of oral misoprostol in third 
stage management. It may also serve as a guide for future 
study design on the subject.
Shivering was significantly higher in the misoprostol group. 
This finding has been reported by earlier studies. However, 
such reports have largely been restricted to studies using 
high dose misoprostol for third stage management.[18,20] It is 
postulated that this may be the effect of prostaglandinE1 on 
central thermoregulatory centers.[22] Some other studies have 
also reported pyrexia as a significant complication, though 
this was not borne from this study.
This study has two major limitations. In the first instance, 
the sample size used in the survey did not evaluate the 
equivalence between the two groups. To achieve this, a much 
larger sample size will be required. This could be achieved 
either in the form of a meta-analysis of previous studies 
or a multicenter collaborative study. The use of clinically 
estimated blood loss and its shortcomings has been noted 
earlier. However, the possible effect of this has been greatly 
minimized by the concomitant use of the hematocrit change 
and this like the clinical estimation of blood loss, has not 
shown significant differences in the two groups.
The lack of an orally active stable uterotonic agent is a major 
impediment to the prevention of PPH in developing countries. 
The results of this trial suggest that oral misoprostol is as 
effective as ergometrine in the prevention of atonic uterus. 
It may, however, have more non-live threatening effects in 
particular shivering.
In conclusion, based on this study, oral misoprostol may be 
recommended for the prevention of PPH, the outcome being 
of similar efficacy to standard management. The same may 
also be applicable to high-risk parturients for PPH in labor. 
The side effects appeared minimal and are far outweighed 
by the potential benefits from its use. There is, however, a 
need for larger studies or a meta-analysis to demonstrate 
equivalence between the two groups.
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